Variants of the CFH gene, encoding complement factor H (CFH), show strong association with age-related macular degeneration (AMD), a major cause of blindness. Here, we used murine models of AMD to examine the contribution of CFH to disease etiology. Cfh deletion protected the mice from the pathogenic subretinal accumulation of mononuclear phagocytes (MP) that characterize AMD and showed accelerated resolution of inflammation. MP persistence arose secondary to binding of CFH to CD11b, which obstructed the homeostatic elimination of MPs from the subretinal space mediated by thrombospsondin-1 (TSP-1) activation of CD47. The AMD-associated CFH(H402) variant markedly increased this inhibitory effect on microglial cells, supporting a causal link to disease etiology. This mechanism is not restricted to the eye, as similar results were observed in a model of acute sterile peritonitis. Pharmacological activation of CD47 accelerated resolution of both subretinal and peritoneal inflammation, with implications for the treatment of chronic inflammatory disease.
In Brief
Variants in complement factor H (CFH) show strong association to age-related macular degeneration. Calippe et al. find that CFH binding to mononuclear phagocytes (MP) curbs the CD47-mediated elimination of MPs that maintains homeostasis in the subretinal space. The AMD-associated CFH variant CFH(H402) increases subretinal MP accumulation, providing insight into disease etiology.
INTRODUCTION
Age-related macular degeneration (AMD) is a heritable neuroinflammatory disorder characterized by deposits of lipoproteinaceous debris called large drusen (early AMD), choroidal neovascularization (wet AMD, late form), and an extending lesion of the retinal pigment epithelium (RPE) and photoreceptors (geographic atrophy, GA, late form) (Sarks, 1976) . Early AMD afflicts more than 150 million people worldwide, and 10 million people suffer from late AMD (Wong et al., 2014) . AMD is strongly associated with common and rare genetic variants of the CFH gene, encoding complement factor H (CFH), suggesting a causal role for alterations in CFH expression or function in the pathogenesis of this disease (Fritsche et al., 2014) . However, the mechanisms through which these alterations may lead to or contribute to AMD are not well understood.
CFH is an abundant soluble plasma factor composed of 20 short consensus repeat domains (SCR) with important roles in inflammation (Kopp et al., 2012) and coagulation (Rayes et al., 2014) and as an antioxidant (Weismann et al., 2011) . The SCR7 domain of CFH binds to glycosaminoglycans (GAG) on cell surfaces, where it inhibits complement activation (Kopp et al., 2012) . This domain also allows CFH to bind to myeloid cells via the integrin CD11b (that forms, with CD18, the complement 3 receptor), supporting myeloid cell adhesion and migration, as well as the phagocytosis of microbes and cell debris (DiScipio et al. CFH is strongly secreted by mononuclear phagocytes (MP), such as microglial cells (MC) and macrophages (M4) (Gautier et al., 2012; Luo et al., 2011; Schlaf et al., 2001 ), adding to the exudated plasma CFH and CFH produced by certain stromal cells such as the retinal pigment epithelium (RPE) in the eye (Anderson et al., 2010) .
A genetic variant that results in the substitution of histidine 402 for tyrosine (Y402H) in the SCR7 domain of CFH is associated with the highest risk of AMD (Fritsche et al., 2014) , as well as with other conditions such as smoking-associated lung cancer (Zhang et al., 2012) and increased mortality after cerebral hemorrhage (Appelboom et al., 2011) . This genetic variant is associated with both early and advanced forms of AMD (Fritsche et al., 2014) , suggesting that CFH(H402) may drive disease onset.
Early and advanced forms of AMD are associated with chronic accumulation of MPs in the subretinal space located between the RPE and photoreceptor outer segments (Combadiè re et al., 2007; Gupta et al., 2003; Lad et al., 2015; Levy et al., 2015a; Sennlaub et al., 2013) . Functional studies in animal models suggest that subretinal MP accumulation plays a critical role in neovascularization and photoreceptor degeneration that characterizes late AMD (Cruz-Guilloty et al., 2013; Sennlaub et al., 2013; Tsutsumi et al., 2003) . Similarly, non-resolving, low-grade inflammation and MP persistence contributes significantly to the pathogenesis of many chronic, age-related diseases such as metabolic diseases (obesity, atherosclerosis), neurodegenerative diseases, and cancers (Nathan and Ding, 2010) . In these settings, MP persistence is not considered causal, but rather is associated with considerable collateral damage to host cells, which fuels further inflammation (Nathan and Ding, 2010) .
Here, we examined the contribution of CFH to the etiology of AMD. We found a noncanonical role for CFH in the regulation of MP accumulation in chronic inflammation and in the resolution of acute inflammation. Our findings shed light on the mechanisms by which CFH(H402) drives sub-retinal inflammation and further suggest that the role for CFH in resolution of inflammation may be relevant in various settings.
RESULTS

CFH Deficiency Prevents Chronic Pathogenic Subretinal Inflammation
Physiologically, the subretinal space is devoid of immune cells, including resident MCs (Combadiè re et al., 2007; Levy et al., 2015a) , due to the potent immunosuppressive proapoptotic factors produced by the RPE that eliminate infiltrating leukocytes (Griffith et al., 1995; Levy et al., 2015a) . We have previously shown that high levels of Apolipoprotein E, as observed in subretinal MPs of AMD patients, Cx3cr1-deficient mice, and humanized transgenic mice expressing the AMD-risk APOE2 isoform (TRE2-mice), induce chronic, age-related, and pathogenic subretinal MP accumulation (Levy et al., 2015a (Levy et al., , 2015b Sennlaub et al., 2013 and RPE flatmounts of 2-to 3-month-and 12-month-old animals showed that the age-related increase in subretinal MPs observed in both models was nearly completely blunted in the absence of CFH ( Figures 1A and 1B) . Micrographs revealed that Cx3cr1 GFP/GFP Cfh À/À mice were protected against the thinning of the outer nuclear layer, which hosts photoreceptor nuclei, usually observed in Cx3cr1 GFP/GFP mice (Sennlaub et al., 2013) ( Figure 1C ). Photoreceptor nuclei row counts ( Figure 1D ) and calculation of the area under the curve showed Cfh deficiency protected against the photoreceptor cell loss observed in Cx3cr1 GFP/GFP mice ( Figure 1E ) and TRE2 mice (Levy et al., 2015b ) ( Figure 1F ), while no difference was observed in Cfh À/À compared to control mice. Similarly, Cfh deficiency completely protected against cone loss observed on peanut agglutinin-, cone arrestin-double-stained labeled retinal flatmounts from 12-month-old Cx3cr1 GFP/GFP mice and TRE2-mice ( Figures  1G-1J ). CFH did not alter the secretion of key pathogenic cytokines by MPs in vitro ( Figure S1 ), confirming that the numerical decrease of MPs, rather than an altered ability to produce inflammatory mediators, protected Cfh deficient animals against the degeneration. Thus, we showed that CFH was required for the chronic, age-related, subretinal MP accumulation and associated photoreceptor degeneration observed in both mouse models of AMD. A similar age-and CFH-dependent increase in MPs was also described in the choroid of Cfh +/À compared to Cfh À/À mice (Toomey et al., 2015) . In humans, ocular CFH immunoreactivity is invariably stronger in AMD donor tissues (Hageman et al., 2005; Johnson et al., 2006; Weismann et al., 2011) and CFH autoantibodies are protective in AMD (Dhillon et al., 2010) . Together with these observations, our results strongly suggest that CFH critically controls subretinal MP accumulation in AMD.
CFH Inhibits the Resolution of Acute Subretinal Inflammation
Next, to better understand how CFH controls subretinal inflammation, we evaluated its impact on acute light-induced stress. The intensity of the light-challenge model used herein was calibrated to induce substantial subretinal MP infiltration in AMDprone Cx3cr1 GFP/GFP and TRE2 mice, but not in controls (Levy et al., 2015b; Sennlaub et al., 2013) Figure 2C ). However, the significant increase in circulating C3 levels did not affect the number of subretinal MPs in Cx3cr1 GFP/GFP Cfh À/À mice at day 14 ( Figure 2D ).
The comparable subretinal MP counts at the beginning of acute inflammation (day 4) (Figures 2A and 2B ) and the lack of influence of circulating C3 levels during the resolution phase ( Figure 2D ) suggested that systemic C3 was not involved in MP recruitment or their elimination. We next assessed relative Cfh mRNA levels in retinal and RPE and choroid tissue homogenates, bone marrow (BM-Mos), and circulating (Mos) monocytes, as well as MCs isolated from the brain and retina. Our Bonferroni test: *p < 0.0001 versus all other groups; Mann-Whitney $ p = 0.0158 versus TRE2 mice). TRE2 and TRE3: targeted replacement mice expressing human APOE 2 and 3 isoforms. ONL: outer nuclear layer; Scale bar A and C, 50 mm. n, number of replicates indicated in the graphs; replicates represent quantifications of eyes from different mice of at least three different cages. All values are reported as mean ± SEM. data showed that RPE and choroid and MCs expressed the highest levels of Cfh mRNA in wild-type (WT) and Cx3cr1 GFP/GFP mice ( Figure 2E ), in accordance with CFH protein localization around subretinal MPs in vivo ( Figure S2 ). To evaluate whether MC-or RPE-derived CFH would impact subretinal MP elimination, we adoptively transferred CFSE-labeled MCs from different mouse strains into the subretinal space of either WT or Cfh À/À mice.
The surviving CFSE + MCs were then enumerated 24 hr after injection. We previously showed that subretinally injected WT Mos, MCs, or Mfs quickly undergo apoptosis and are eliminated (Levy et al., 2015a) , and that such clearance is significantly delayed when MPs lack CX3CR1 (Levy et al., 2015a). We found that Cx3cr1 GFP/GFP MCs lacking Cfh were eliminated faster than controls ( Figure 2F ). This difference could be reversed by human CFH ( Figure 2F ). Experiments using BM-Mos revealed comparable results ( Figure S3 ). Interestingly, recipient-derived CFH only had a very minor impact on MC elimination ( Figure 2F ), suggesting that MP-derived CFH is more important. Similarly, TRE2 Cfh À/À MCs injected in WT recipients were eliminated faster than controls, and adding CFH protein again reversed the effect ( Figure 2G ). In summary, our data showed that CFH did not influence initial MP recruitment but inhibited MP elimination during inflammation resolution. They also demonstrated that RPE-and liver-derived CFH had little influence on this phenotype. Indeed, MP-derived CFH was sufficient to inhibit MP clearance. Similar to our experiments, the observation that recipient, but not liver Cfh genotype, confers the AMD-risk in liver transplant patients (Khandhadia et al., 2013) suggests that plasma CFH is not involved in AMD pathogenesis and points to the importance of MP-derived CFH in the disease.
CFH Binding to CD11b Inhibits MP Elimination Mediated by TSP-1 Activation of CD47 CFH can act as a cofactor of complement factor I (CFI) to cleave C3b into iC3b, which reduces C3 convertase formation, formed by C3b and activated complement factor B (CFB) and opsonizes (iC3b) apoptotic bodies (Martin and Blom, 2016) . However, we did not detect C3 or activated C3 fragments in subretinal MPs of Cx3cr1 GFP/GFP or Cx3cr1 GFP/GFP Cfh À/À mice ( Figure S3 ), and BM-Mos and MCs only expressed low and very low levels of C3 mRNA and no detectable levels of Cfi mRNA in both cell types ( Figure S4 ). Together, these observations made a significant implication of locally produced C3, C3b, or iC3b in CFHmediated inhibition of MP elimination unlikely. CFH also binds directly to the integrin CD11b (DiScipio et al., 1998; Kang et al., 2012; Losse et al., 2010 ) that was strongly expressed by MPs with no detectable differences in our mouse strains ( Figure S5 ). Flow cytometry analysis showed fluorescently labeled CFH bound dose-dependently to MCs ( Figure 3A ) and BM-Mos isolated from Cx3cr1 GFP/GFP Cfh À/À mice (Figure 3B ). Pre-incubation with an anti-CD11b antibody inhibited CFH binding ( Figure 3B ), as previously demonstrated for neutrophils (DiScipio et al., 1998). As shown above ( Figure 2F ), adding CFH to Cx3cr1 GFP/GFP Cfh À/À MCs transferred subretinally in WT recipients delayed their elimination. This effect was no longer observed when transferred MPs were treated with the antiCD11b antibody ( Figure 3C ). The antibody also significantly accelerated the elimination of CFH-competent Cx3cr1
GFP/GFP
MCs. By contrast, an anti-C3b/iC3b/C3c antibody that inhibits complement-induced hemolysis (clone 3/26 (Mastellos et al., 2004 ) had no effect ( Figure 3C ). These results revealed that CFH binding to the CD11b integrin was necessary to inhibit MC elimination and suggested a C3-independent, non-canonical role of CFH in this mechanism. CD11b co-localizes with the integrin-associated protein (IAP, CD47) in lipid rafts (Pfeiffer et al., 2001 ), a thrombospondin 1 (THBS1, TSP-1) receptor known to potentiate FasL-induced endothelial cell and T cell death (Manna et al., 2005; Quesada et al., 2005) . We therefore investigated whether CFH binding to CD11b could limit CD47 activation and impair MP elimination in Cx3cr1 GFP/GFP and TRE2 mice. First, we found the expression level of TSP-1 and CD47, as well as the plasma TSP-1 levels, were similar in our different mouse strains ( Figure S5 ). Next, proximity ligation assay revealed numerous complexes formed by CD11b and CD47 on Cx3cr1 GFP/GFP Cfh À/À MCs ( Figure 3D ).
We next analyzed the role of CD47 in subretinal MC clearance in adoptive transfer experiments. Subretinally injected CFSElabeled MCs from WT, Thbs1 À/À , or Cd47 À/À donors into WT recipients revealed that MCs lacking Thbs1 or Cd47 had slower elimination rates than WT MCs ( Figure 3E ). Co-injected recombinant TSP-1 accelerated the elimination of WT MCs and reversed the phenotype of Thbs1-deficient MCs, but had no effect on MCs lacking Cd47 ( Figure 3E ), suggesting the interaction of TSP1 with CD47-mediated MC elimination. Moreover, analysis of Thbs1
and Cd47 À/À mice revealed a significant age-related ( Figure 3F) and light-induced ( Figure 3G ) increase in subretinal MPs in these strains as compared to controls, but not in mice lacking Cd36, an alternative TSP-1 receptor. Overall, our results pointed to TSP-1 activation of CD47 as central in the maintenance of subretinal immunosuppression. Our results also likely explained the previously reported increased and prolonged subretinal inflammation observed in Thbs1 À/À mice (Chen et al., 2012; Ng et al., 2009; Wang et al., 2012) . Interestingly, binding of TSP-1 to CD36 that mediates endothelial cell apoptosis and is necessary for latent TGF-b activation (Febbraio et al., 2001) had no significant influence on subretinal MP accumulation, as observed here in Cd36 À/À mice.
Taking into account the opposing effects of TSP1 and CFH, we next evaluated their interaction in MP elimination. Using our adoptive transfer assay, we found that a TSP-1 blocking antibody reversed the accelerated elimination of Cx3cr1 GFP/GFP Cfh À/À MCs compared to controls ( Figure 3H ). Furthermore, the faster elimination rate observed after supplementation of recombinant TSP-1 to Cx3cr1 GFP/GFP Cfh À/À MCs was completely lost when purified CFH was concomitantly added ( Figure 3I ). Next, we used the laser-injury model to test whether CFH binding to CD11b or CD47 activation can accelerate , Cd47 À/À mice, and Cd36 À/À mice at (F) 2 to 3 months and 12 months and (G) after a 4-day light challenge, followed by 10 days of recovery (n = replicates represent quantifications of eyes from different mice of at least three different experiments and cages; one-way Anova/Bonferroni test F: *p < 0.0001 versus 2-to 3-month-old Thbds1 À/À mice and 12-month-old C57BL6/J mice; inflammation resolution in CFH-competent Cx3cr1 GFP/GFP mice. Using this model, we take advantage of the fact that laser burn induces a thinning of the retina above the impact, facilitating diffusion of intravitreally injected molecules to the subretinal space. Our results showed that TSP-1 (Figure 3J ), CD47-activating peptide PKHB1 (a derivate of the 4N1K CD47-agonist peptide with improved pharmacological properties [Denè fle et al., 2016] , Figure 3K ), or the anti-CD11b antibody (that blocks CFH binding to CD11b, Figure 3L ), injected at the height of laserinduced subretinal inflammation (d4 and d7), all significantly accelerated subretinal MP elimination as compared to their controls.
Taken together, our data showed that CFH binding to the integrin CD11b inhibited subretinal MC elimination. We demonstrated that CD47 co-localized with CD11b on MPs and mediated the physiological role of TSP-1 in subretinal MP elimination. The observation that TSP-1 blockade reversed the effect of CFH deficiency and that recombinant CFH blocked the effect of TSP-1 on subretinal MP elimination strongly suggested that CFH binding to CD11b interfered with TSP-1 activation of CD47. We showed that TSP-1 and more specifically CD47 activation efficiently accelerated MP elimination similar to Cfh deficiency.
CFH Inhibits the Resolution of Acute Sterile Peritonitis
Non-resolving inflammation contributes significantly to the pathogenesis of many chronic, age-related diseases (Nathan and Ding, 2010) . To test whether CFH influences inflammation resolution in other pathological contexts, we used a model of acute thioglycollate-induced peritonitis, characterized by an early accumulation of neutrophils, followed by recruited monocytederived inflammatory macrophages (recM4), both experiencing an apoptosis-driven elimination at different kinetics (Gautier et al., 2013) . Analysis of the ImmGen dataset (Gautier et al., 2012) (GenBank: GSE37448) showed that Cfh mRNA levels in thioglycollate-elicited peritoneal recM4 were approximately doubled compared to circulating blood Ly-6C + Mo, from which they derive ( Figure 4A ). Thus, recM4s likely participate to local CFH in peritonitis, in addition to extravasated plasma CFH. Quantification of recruited CD115 + F4/80 + ICAM2 lo recM4s in Cfh À/À mice and controls ( Figure 4B ) revealed a robust and similar early accumulation 1 day after peritonitis induction (Figure 4C) . At day 3, however, while the numbers of recM4s continued to rise in WT mice, they had receded by 50% in Cfh À/À mice ( Figure 4C ). This observation was similar to the accelerated elimination of subretinal MPs observed in light-challenged TRE2 Cfh À/À and Cx3cr1 GFP/GFP Cfh À/À mice (Figures 2A   and 2B ). Human recombinant CFH injected into the peritoneal cavity of Cfh À/À mice at day 1 significantly inhibited the enhanced clearance of recM4s observed in this strain at day 2 as compared to heat-denatured CFH ( Figure 4D ), akin to the effect we observed in subretinally injected Cx3cr1 GFP/GFP Cfh À/À MCs ( Figure 2F ). In addition, similar to our results in MCs (Figure 3D) , a proximity ligation assay revealed numerous and specific complexes CD11b and CD47 in WT recM4 retrieved at day 1 ( Figure 4E ). Finally, a single intraperitoneal (i.p.) injection of recombinant TSP-1 or the CD47-specific activating peptide PKHB1 at day 1 significantly accelerated the elimination of recM4s as observed at day 2 ( Figure 4F ).
In summary, our results showed that CFH inhibited recM4 elimination in sterile peritonitis, confirming findings for infiltrating MPs in the subretinal space. The observation that complexes of CD11b and CD47 were present on peritoneal recM4 and that CD47 activation accelerated recM4 elimination during peritonitis strongly suggested that CFH inhibited CD47-dependent inflammation resolution similarly in both the eye and the peritoneum.
The CFH(H402) Variant Inhibits Subretinal MC Elimination More Potently than the Common CFH(Y402)
The substitution of histidine 402 for tyrosine (Y402H) in the CFH sequence accounts for a major part of the genetic risk of AMD. To test whether the Y402H polymorphism influenced the elimination of distinct MPs differently, we transferred CFSE-labeled Cx3cr1 GFP/GFP Cfh À/À MCs or BM-Mos to the subretinal space together with purified CFH(Y402) or the disease associated CFH(H402) to WT mice. CFSE + cell counts after 24 hr revealed that both isoforms inhibited clearance of BM-Mos ( Figure 5A ) and MCs ( Figure 5B ) compared to cells injected without CFH. However, while CFH(Y402) and CFH(H402) had similar effects on BM-Mo elimination ( Figure 5A ), CFH(H402) limited MC clearance by 37% compared to CFH(Y402) ( Figure 5B ). In addition, recombinant CFH(Y402) reversed the accelerated elimination rate observed when subretinally injected Cx3cr1 GFP/GFP Cfh
MCs were treated with recombinant TSP-1, and recombinant CFH(H402) was 50% more potent at inhibiting this phenomenon ( Figure 5C ). Taken together, our results showed that CFH(H402) was significantly more potent to inhibit the subretinal elimination of certain MPs, such as MCs. The CFH(H402) variant might thereby spur non-resolving inflammation under the retina and thus explain its association with early and late AMD (Fritsche et al., 2014) where subretinal MPs accumulate (Lad et al., 2015; Levy et al., 2015a; Sennlaub et al., 2013) .
DISCUSSION
We report the previously unknown ability of CFH to favor subretinal MP accumulation in mice developing chronic, nonresolving, age-related inflammation in the eye. We extended this finding to inflammation resolution in general by using models of acute inflammation in the peritoneum and the eye. Our work supports the long-standing association between CFH variant and AMD, and we uncovered the mechanisms by which CFH impacts MP infiltration independently from its action in the complement cascade.
The subretinal space is prone to MP infiltration due to light-induced oxidative stress and high metabolic activity (Combadiè re et al., 2007; Ng and Streilein, 2001) , and this is physiologically counterbalanced by the expression of immunesuppressive factors by the RPE (Griffith et al., 1995; Levy et al., 2015a) . We showed that CFH favored MP accumulation by inhibiting their elimination mediated by TSP-1 activation of CD47.
Remarkably, Thbs1
À/À and Cd47 À/À mice developed age- (Griffith et al., 1995; Levy et al., 2015a) . CFH was expressed at high levels in MCs and Mo-derived M4s in peritonitis, and we confirmed a stepwise binding interaction between CFH and CD11b (Gautier et al., 2012; Luo et al., 2011; Schlaf et al., 2001 ) and CD11b and CD47 (Pfeiffer et al., 2001) on MPs. The ligation of the sizeable CFH (1231 amino acids) to CD11b might thereby sterically hinder the ligation of the trimeric TSP-1 (3 3 1106 amino acids) to CD47 and increase MP lifespan. Although the exact mechanism remains to be elucidated, our data show that complement activation or CFHdependent production of iC3b, an alternative ligand of CD11b, did not play a detectable role in the process: C3b, iC3b, or C3c fragments were not found in the subretinal space, and CFI (necessary to produce iC3b) was not significantly transcribed in MPs. Lastly, a specific antibody that inhibits the alternative cascade (Mastellos et al., 2004) did not accelerate MP elimination.
In addition, we found that the AMD-associated CFH(H402) variant had an increased capacity to inhibit the elimination of certain MP populations, such as MCs, strengthening the causal link to AMD etiology. Although CFH(H402) affinity is decreased to certain GAG species, it is higher in particular to GAG sulfates (Clark et al., 2006) . GAG sulfate profiles differ greatly between MPs and different microenvironments. For example, keratan sulfate proteoglycans (KPSG) are strongly present on ramified brain MCs, but not on blood Mos (Wilms et al., 1999) . The differential expression of GAG sulfates, such as KPSG, on MCs might M4: macrophage; Mo: monocyte; Thio: thioglycollate; MHC: major histocompatibility complex; dCFH: heat-denatured CFH; negCTL: negative control. n = number of replicates indicated in the graphs; replicates represent quantifications of exudate cells from different mice of three (C) or two (E and F) different peritonitis inductions. Scale bar, E = 10 mm. All values are reported as mean ± SEM. explain why CFH(H402) differentially influenced MC, but not BM-Mos, elimination. Subretinal MPs originating from infiltrating Mo and MCs (Sennlaub et al., 2013) invariably express KPSG strongly (Combadiè re et al., 2007; Ng and Streilein, 2001; Ng et al., 2009) . This is also the case in spinal cord injury, but not in autoimmune neuritis (Jones and Tuszynski, 2002; Matsui et al., 2013) . CFH(H402) might therefore have a particularly strong influence on subretinal inflammation observed in AMD, but not necessarily in other chronic inflammatory diseases. In human evolution, the limited elimination of MPs and the increased inflammatory reaction associated with CFH(H402) might have increased survival to certain infectious diseases, leading to its high frequency as observed today in certain populations. In AMD, CFH(H402) might be pathogenic, as it fuels subretinal inflammation and leads to chronic inflammation, which add to its decreased capacity to inhibit oxidative stress (Weismann et al., 2011) and to bind to Bruchs membrane (Clark et al., 2010) that protects the RPE against uncontrolled complement activation (Coffey et al., 2007; Toomey et al., 2015) .
Current anti-inflammatory therapies, such as steroids, nonsteroidal anti-inflammatory drugs (NSAID), or immunosuppressive drugs (Ciclosporin) can have paradoxical effects on macrophage function. They increase proinflammatory mediators (high-dose steroids) (Lim et al., 2007) , upregulate toll-like receptors on macrophages (Ciclosporin) (Tedesco and Haragsim, 2012) , and prolong macrophage infiltration (NSAID) (Gilroy et al., 1999) , which might explain their lack of therapeutic effect in AMD. Our findings introduce a new strategy to directly induce the elimination of pathogenic macrophage accumulation in AMD, and possibly other conditions, by pharmacological activation of CD47. , and TRE2 Cfh À/À mouse strains were generated, all mice were either negative or backcrossed to eliminate the Pde6b rd1 , Gnat2 cpfl3 , and Crb1 rd8 mutations. The mice were kept to the indicated ages under specific pathogen-free condition in a 12 hr/12 hr light/dark (100 lux) cycle with no additional cover in the cage and with water and normal chow diet available ad libitum.
Aging, Light Challenge-, and Laser-Injury Model Mice were exposed to green LED light (4500 Lux) for 4 days and subsequently kept in cyclic conditions (Sennlaub et al., 2013) . Laser-coagulations were performed on male mice (Vitra Laser, 532 nm, 450 mW, 50 ms, and 250 mm), which were intravitreally injected (days 4 and 7) with 2 mL of PBS, recombinant human TSP-1 (10 mg/mL), the 4NGG control peptide or the PKHB1 CD47-activating peptide (200 mM), anti-CD11b antibody (50 mg/mL), and isotype control rat IgG2 (50 mg/mL) and sacrificed at day 10. All experimental procedures were approved by the local animal care ethics committee C2EA-05-Charles Darwin.
Histology and Immunohistochemistry
After fixation, the eyes were cryo-sectioned (10 mm) and stained with anti-C3-, anti-C3b/iC3b/C3c-, and anti-CFH-antibodies and appropriate secondary antibodies or dissected for flatmount preparations. The retinas and choroids were incubated with peanut agglutinin, anti-IBA-1, anti-cone arrestin, or anti-CD102 antibodies as indicated, followed by appropriate conjugated secondary antibodies. IBA-1 + cells were counted on whole RPE/choroidal flatmounts and on the outer segment side of the retina. PA + cone arrestin + cells were counted on oriented retinal flatmounts. For histology, the eyes were fixed, embedded in Historesin, cut (5 mm sagittal sections), and stained with toluidin blue. Rows of nuclei in the outer nuclear layer (ONL) were counted at different distances from the optic nerve.
Hydrodynamic Injection
Empty pLIVE plasmid and coding for murine CFH was intravenously injected to mice, as previously described (Rayes et al., 2010) . Four days later, mice were exposed to the light challenge model, and their blood was sampled to quantify plasma C3 concentration by ELISA.
Plasma and Mononuclear Phagocyte Preparations, Analysis, and Culture Plasma C3 and TSP-1 levels were measured by ELISA. Mos from the blood and bone marrow were isolated by negative selection. MCs from brain and retina were isolated with anti-CD11b microbeads. No (CFH-containing) serum was used in any step of the purification. Cells were used for adoptive transfer experiments, analyzed by RT-qPCR or cultured for 24 hr in serum-free DMEM in the presence of recombinant human APOE3, and finally, their supernatants were analyzed by cytokine multiplex array. 
Subretinal Adoptive Microglial Cell Transfer and Clearance
Brain MCs from male mice were sorted, labeled with CFSE, and injected in the subretinal space (verified by fundoscopy) of WT or Cfh À/À male mice in 4 mL of PBS, purified human or recombinant CFH, CFH(Y402), and CFH(H402) (500 mg/mL), recombinant human TSP-1 (10 mg/mL), and following antibodies (10 mg/mL); anti-CD11b, anti-C3b/iC3b/C3c, isotype control rat IgG2, anti-TSP-1, and isotype control mouse IgM. After 24 hr, CFSE + cells in the subretinal space were quantified on whole RPE/choroidal and retinal flatmounts.
Thioglycollate-Induced Peritonitis and Flow Cytometry Peritonitis was induced by i.p. injections of 0.5 mL of 3% (weight/volume) thioglycollate broth in male mice. At 24 hr, mice were injected with 100 mL of PBS containing native or heat inactivated purified commercial human CFH (500 mg/mL), recombinant human TSP-1 (50 mg/m), the CD47-activating peptide PKHB1, or the 4NGG control peptide (500mM), and exudate cells were analyzed using a BD Fortessa flow cytometer.
CFH Binding Assay by Flow Cytometry
MCs from Cx3cr1 GFP/GFP Cfh À/À were stained 30 min with Cy5.5-conjugated human CFH at 37 C and washed before acquisition on a BD Fortessa flow cytometer. Bone marrow monocytes were preincubated with control IgG or antiCD11b antibody (clone 5C6) at 10 mg/mL and incubated with hCFH-Cy3.
CD11b-CD47 Proximity Ligation Assay
Duolink PLA assay was performed following the manufacturer's instructions with rabbit anti-CD11b and goat anti-CD47 on day 1 thioglycollate elicited peritoneal M4s and brain MCs.
Statistical Analysis
Graph Pad 7 (GraphPad Software) was used for data analysis and graphic representation. All values are reported as mean ± SEM. Statistical analysis and variance analysis was performed by one-way ANOVA, followed by Bonferroni post-test (for multiple comparison) or Mann-Whitney U-test (two-group comparison) among means depending on the experimental design. The n and p values are indicated in the figure legends. Please see Supplemental Information for more details.
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